$120.85$150.99
Prepare to embark on a sensory journey with the Bosco Apple, a fruit that transcends the ordinary and promises an unparalleled taste experience. These apples are nothing short of nature’s masterpiece, celebrated for their distinctive blend of flavors and their captivating visual allure.
Availability: In Stock
Subscribe to out newsletter today to receive latest news administrate cost effective for tactical data.
₹682
INTRODUCTION ENCICARB 100MG contains Ferric carboxymaltose which belongs to the group of medicines called Iron replacement medicines. It is used to treat iron deficiency anaemia (IDA) in adults and in children (above 14 years of age), who are unable to take iron supplements orally, have an int...
ENCICARB 100MG contains Ferric carboxymaltose which belongs to the group of medicines called Iron replacement medicines. It is used to treat iron deficiency anaemia (IDA) in adults and in children (above 14 years of age), who are unable to take iron supplements orally, have an intolerance to oral iron supplements, need a rapid iron supplement in the body, have non-dialysis dependent chronic kidney disease. Iron deficiency anaemia is a condition in which the body lacks enough amount of iron, which is essential for the production of red blood cells and transport of oxygen in the body.
Your doctor may advise you to take relevant tests to understand your existing condition. Before receiving ENCICARB 100MG inform your doctor if you are pregnant or planning to get pregnant or breast-feeding. ENCICARB 100MG is not recommended for use in children and adolescents (under 14 years of age) and it should be used with caution in elderly patients (aged 65 years or above). Consult your doctor before receiving ENCICARB 100MG.
The most common side effects of receiving ENCICARB 100MG may include headache, dizziness, flushing, high blood pressure, nausea and injection or infusion site reactions. Consult your physician if any of the symptom worsens.
ENCICARB 100MG contains iron (III) hydroxide complexed with a carbohydrate polymer called carboxymaltose, which is capable of releasing iron. The iron released from the complex helps in the synthesis of haemoglobin and increases red blood cell count. As a result, it treats iron deficiency anaemia.
ENCICARB 100MG will be given to you only by a doctor or a nurse into a vein as an intravenous injection or infusion. Your physician will decide the correct dose and duration for you depending upon your age, body weight and severity of the condition.
Contact your doctor immediately if you experience any of the following side effects:
Headache:
Take rest and relax. Drink plenty of fluids such as water. Apply a pain-relieving balm on the forehead if necessary. Consult your doctor if your headache does not improve.
Nausea or vomiting:
Stick to simple meals. Avoid eating oily, fried or spicy foods. Do not lie down or sleep immediately after eating. Consult your doctor if the symptom does not improve.
Stomach pain:
Try to take rest and relax. Eat and drink slowly or try to have smaller and frequent meals. Keep a heat pad on your stomach. If the symptom does not improve, consult your doctor.
Diarrhoea:
Drink lot of fluids, such as water or fruit juices to keep yourself hydrated. Avoid eating high-fat or spicy foods. If the symptom does not improve, consult your doctor.
Constipation:
Take fiber rich foods in your diet such as fresh fruits, vegetables and whole grain cereals, and drink plenty of fluids. Consult your doctor if the symptom does not improve.
ENCICARB 100MG should be used with caution in pregnant women only if considered clearly necessary. Inform your doctor if you are pregnant, think you may be pregnant, or planning to have a baby. Consult your doctor before receiving ENCICARB 100MG.
If you are breastfeeding, consult your doctor for advice before receiving ENCICARB 100MG. It is unlikely that ENCICARB 100MG represents a risk to the breast-fed child.
ENCICARB 100MG is unlikely to impair the ability to drive or operate machines.
ENCICARB 100MG should be used with caution in patients with chronic kidney disease who are dependent of haemodialysis treatment. Consult your doctor before receiving ENCICARB 100MG.
ENCICARB 100MG should be used with caution in patients with liver disease. Consult your doctor before receiving ENCICARB 100MG.
Do not receive ENCICARB 100MG if you are allergic to ferric carboxymaltose or any of the other ingredients of this medicine or if you have experienced serious allergic reactions to other injectable iron preparations.
ENCICARB 100MG should be used with caution in patients with severe asthma. Consult your doctor before receiving ENCICARB 100MG.
ENCICARB 100MG is not recommended for use if you have:
Before receiving ENCICARB 100MG inform your doctor if you have:
Use in paediatrics:
ENCICARB 100MG is not recommended for use in children (under 14 years of age). Consult child’s doctor for advice to treat the condition.
Use in geriatrics:
ENCICARB 100MG should be used with caution in elderly patients (aged 65 years or above). Consult your doctor before receiving ENCICARB 100MG.
A. Drug-Drug interactions:
Before receiving ENCICARB 100MG, inform your doctor if you are using or have recently taken any other medicines including prescription, non-prescription medicines and vitamins or herbal supplements.
Overdosage:
ENCICARB 100MG will be administered to you only by a doctor or a nurse in a hospital, and so it is unlikely to receive an overdose. However, consult your doctor or nurse if you experience any unusual symptoms.
| Drug | : | Ferric carboxymaltose |
| Pharmacological Category | : | Iron replacement medicines |
| Therapeutic Indication | : |
Iron Deficiency Anemia (IDA) |
| Dosage Forms | : |
Injection |
How does ENCICARB 100MG work?
ENCICARB 100MG contains iron (III) hydroxide complexed with a carbohydrate polymer called carboxymaltose, which is capable of releasing iron. The iron released from the complex helps in the synthesis of haemoglobin and increases red blood cell count. As a result, it treats iron deficiency anaemia.
Is ENCICARB 100MG safe to use in patients with kidney problems?
ENCICARB 100MG should be used with caution in patients with chronic kidney disease who are dependent of haemodialysis treatment. Consult your doctor before receiving ENCICARB 100MG.
Who should avoid receiving ENCICARB 100MG?
ENCICARB 100MG is not recommended for use in patients with evidence of iron overload or disturbances in the utilisation of iron, anaemia not attributed to iron deficiency (microcytic anaemia) and with known allergic to ferric carboxymaltose or serious allergic to other parenteral iron products.
Is ENCICARB 100MG safe to use in elderly patients?
ENCICARB 100MG should be used with caution in elderly patients (aged 65 years or above). Your doctor may monitor you carefully during administration and certain time after administration of ENCICARB 100MG. Consult your doctor before receiving ENCICARB 100MG.
Can ENCICARB 100MG be used during pregnancy?
ENCICARB 100MG should be used with caution in pregnant women only if clearly advised by your doctor. Inform your doctor if you are pregnant, think you may be pregnant, or planning to have a baby. Consult your doctor before receiving ENCICARB 100MG.
1. KD. Tripathi. Haematinics and Erythropoietin. Essentials of medical pharmacology. Seventh edition. 2013. Page – 605.
2. Joao Ricardo Friedrischa and Rodolfo Delfini Cancadob. Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia. NIH. National Library of Medicine, National Center for Biotechnology Information. PMC PubMed Central. October 2015. [Accessed on 1st July 2022] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678908/
3. American Regent, Inc. Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia. NIH. U.S. National Library of Medicine. ClinicalTrials.gov. [Revised in February 2018] [Accessed on 1st July 2022] https://clinicaltrials.gov/ct2/show/NCT00703937
4. Vifor France. Electronic Medicines Compendium (EMC). [Revised in November 2021] [Accessed on 1st July 2022] https://www.medicines.org.uk/emc/files/pil.5910.pdf
5. Vifor (International) Inc. U.S. Food & Drug Administration. [Revised in April 2021] [Accessed on 1st July 2022] https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203565s014lbl.pdf